Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell nucleus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Cell nucleus. Displaying page 1 of 1.
    EudraCT Number: 2012-000155-14 Sponsor Protocol Number: V2.0 Start Date*: 2013-12-13
    Sponsor Name:Med. Universität Wien, Universitätsklinik für Innere Medizin II
    Full Title: In vivo assessment of the molecular mechanism of inhaled combination of beclomethasone and formoterol on cell differentiation factors and airway remodelling in COPD
    Medical condition: COPD
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2022-004130-19 Sponsor Protocol Number: CTRIAL-IE-22-04/NRG-HN009 Start Date*: 2023-05-24
    Sponsor Name:Cancer Trials Ireland
    Full Title: NRG-HN009: RANDOMIZED PHASE II/III TRIAL OF RADIATION WITH CISPLATIN AT 100 MG/M2 EVERY THREE WEEKS VERSUS RADIATION WITH WEEKLY CISPLATIN AT 40 MG/M2 FOR PATIENTS WITH LOCOREGIONALLY ADVANCED SQUA...
    Medical condition: Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN): Pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma of the head and neck (SCC...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002665-35 Sponsor Protocol Number: 190619 Start Date*: 2019-10-14
    Sponsor Name:Mikkel Holm Vendelbo
    Full Title: 16α-18F-fluor-17β-estradiol PET/CT for detection of estrogen receptor positive liver metastases in breast cancer
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-004400-19 Sponsor Protocol Number: 1707-FIVI-084-MV Start Date*: 2019-05-30
    Sponsor Name:IVIRMA MADRID
    Full Title: Study of the effects of telomerase reactivation with Danazol on ovarian function. A Pilot Study.
    Medical condition: low ovarian reserve
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10036602 Premature ovarian failure LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001220-30 Sponsor Protocol Number: EGF117165 Start Date*: 2014-07-25
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: An Open-Label, Phase II, Study to Evaluate Biomarkers Associated with Response to Subsequent Therapies in Subjects with HER2-Positive Metastatic Breast Cancer Receiving Treatment with Trastuzumab i...
    Medical condition: HER2 positive Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended) IT (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003874-29 Sponsor Protocol Number: E-3810-II-02 Start Date*: 2014-01-20
    Sponsor Name:EOS S.p.A.
    Full Title: A single arm, open-label, phase II study to assess the efficacy of the dual VEGFR-FGFR tyrosine kinase inhibitor, lucitanib, given orally as a single agent to patients with FGFR1-driven lung cancer
    Medical condition: FGFR1-amplified squamous non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-004930-39 Sponsor Protocol Number: G1T28-208 Start Date*: 2021-09-30
    Sponsor Name:G1 Therapeutics, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metasta...
    Medical condition: Locally Advanced Unresectable or Metastatic Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10084066 Triple negative breast cancer metastatic LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BG (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-002092-25 Sponsor Protocol Number: 9766 Start Date*: 2018-06-18
    Sponsor Name:University Hospital of Montpellier
    Full Title: A phase 2/3 prospective, multicentre randomized, double-blind trial, comparing intra-discal allogeneic adult BM-MSC therapy and sham-treated controls in subjects with chronic low back pain due to l...
    Medical condition: Degenerative Disc Disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) DE (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001902-14 Sponsor Protocol Number: D5760C00001 Start Date*: 2017-11-06
    Sponsor Name:MedImmune LLC, a wholly owned subsidiary of AstraZeneca PLC
    Full Title: A Phase 1/2 Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI4276 in Subjects with Select H...
    Medical condition: HER2 expressing Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066896 HER-2 positive gastric cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 100000016800 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005386-67 Sponsor Protocol Number: 20140318 Start Date*: 2017-03-27
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 1b/2, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination With Systemic Pembrolizumab in Phase 1b an...
    Medical condition: Hepatocellular carcinoma (HCC) and metastatic liver tumors (non-HCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    21.0 100000004864 10025628 Malignant liver tumour non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-000113-20 Sponsor Protocol Number: ABI-007-MBC-001 Start Date*: 2013-07-23
    Sponsor Name:Abraxis BioScience, LLC, a wholly-owned subsidiary of Celgene Corporation
    Full Title: A PHASE 2/3, MULTI-CENTER, OPEN-LABEL, RANDOMIZED STUDY OF WEEKLY nab®-PACLITAXEL IN COMBINATION WITH GEMCITABINE OR CARBOPLATIN, COMPARED TO GEMCITABINE/CARBOPLATIN, AS FIRST LINE TREATMENT IN SUB...
    Medical condition: ER, PgR, and HER2 negative (triple negative) metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004872 10006289 Benign and malignant breast neoplasms HLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Prematurely Ended) ES (Completed) DE (Prematurely Ended) GB (Prematurely Ended) IT (Completed) PT (Prematurely Ended) GR (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-000564-81 Sponsor Protocol Number: EGF106903 Start Date*: 2008-01-14
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A randomised, multicentre, open-label, phase III study of neoadjuvant lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer
    Medical condition: Women with primary ErbB2 overexpressing and/or gene amplified breast cancer > 2 cm diameter who have not undergone previous treatment for invasive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) DE (Completed) BE (Completed) GB (Completed) LT (Completed) GR (Prematurely Ended) HU (Completed) ES (Completed) IT (Completed) SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 21:57:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA